Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?

  • J. Ruiz-Ramos
  • P. Vidal-Cortés
  • A. Díaz-Lamas
  • R. Reig-Valero
  • F. Roche-Campo
  • M. Del Valle-Ortiz
  • X. Nuvials-Casals
  • M. Ortiz-Piquer
  • D. Andaluz-Ojeda
  • L. Tamayo-Lomas
  • M. A. Blasco-Navalpotro
  • M. Rodriguez-Aguirregabiria
  • J. Aguado
  • P. RamirezEmail author
Original Article


The use of vancomycin minimum inhibitory concentration (MIC) as an outcome predictor in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia has become an important topic for debate in the last few years. Given these previous results, we decided to investigate whether MICs to vancomycin or daptomycin had any effect on the evolution of patients with ventilator-associated pneumonia (VAP) due to MSSA. An observational, retrospective, multicenter study was conducted among patients with MSSA VAP. We analyzed the relationship between vancomycin and daptomycin MICs and early clinical response (72 h), 30-day mortality, intensive care unit (ICU) length of stay (LOS), and duration on mechanical ventilation. Univariate and multivariate analyses were performed. Sixty-six patients from 12 centers were included. Twenty-six patients (39%) had an infection due to MSSA strains with a vancomycin MIC ≥1.5 μg/mL. Daptomycin MIC was determined in 58 patients, of whom 17 (29%) had an MIC ≥1.0 μg/mL. Ten patients (15%) did not respond to first-line treatment. Only daptomycin MIC ≥1.0 μg/mL had a significant association [odds ratio (OR): 30.00; 95% confidence interval (CI): 2.91–60.41] with early treatment failure. The 30-day mortality was 12% (n = 8). Any variable was associated with mortality in the multivariate analysis. None of the variables studied were associated with ICU LOS or duration on mechanical ventilation. In patients with MSSA VAP, vancomycin MIC does not influence the response to antibiotic treatment or the 30-day mortality. Daptomycin MIC was directly related to early treatment failure.


Minimum Inhibitory Concentration Vancomycin Daptomycin Early Treatment Failure Vancomycin Minimum Inhibitory Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Felipe Bobillo-Del Amo. (Intensive Care Unit, Hospital Clínico Universitario Valladolid, Spain), Lorena del Río-Carbajo (Intensive Care Unit, Complexo Hospitalario Universitario de Ourense), Sergio Ossa-Echeverri (Intensive Care Unit, Hospital Universitario de Burgos, Burgos, Spain), Víctor José López-Ciudad (Intensive Care Unit, Complexo Hospitalario Universitario de Ourense, Spain), Enrique Alemparte Pardavila (Intensive Care Unit, Complexo Hospitalario Universitario A Coruña, La Coruña, Spain), Jaime Torres-García (Microbiology Department, Hospital Universitario General de Castellón, Spain), Zaída García-Reig (Intensive Care Unit, Hospital Universitario General de Castellón, Spain), Marta Dominguez-Gil (Microbiology Department, Hospital Universitario Río Hortega de Valladolid, Spain), Juan Frasquet (Microbiology Department, Hospital La Fe, Valencia, Spain).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of study, formal consent is not required.


  1. 1.
    American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416CrossRefGoogle Scholar
  2. 2.
    Rosenthal VD, Maki DG, Mehta Y et al (2014) International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007–2012. Device-associated module. Am J Infect Control 42:942–956CrossRefPubMedGoogle Scholar
  3. 3.
    Esperatti M, Ferrer M, Theessen A et al (2010) Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 182:1533–1539CrossRefPubMedGoogle Scholar
  4. 4.
    Chang FY, Peacock JE Jr, Musher DM et al (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333–339CrossRefGoogle Scholar
  5. 5.
    Stryjewski ME, Szczech LA, Benjamin DK Jr et al (2007) Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190–196Google Scholar
  6. 6.
    Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ (2007) Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 51:3731–3733CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ (1997) Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17:990–997PubMedGoogle Scholar
  8. 8.
    Aguado JM, San-Juan R, Lalueza A et al (2011) High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 17:1099–1102CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Holmes NE, Turnidge JD, Munckhof WJ et al (2013) Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 19:1163–1168CrossRefPubMedGoogle Scholar
  10. 10.
    Cervera C, Castañeda X, de la Maria CG et al (2014) Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 58:1668–1675CrossRefPubMedGoogle Scholar
  11. 11.
    Haque NZ, Arshad S, Peyrani P et al (2012) Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol 50:1640–1644CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC (2006) An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 42:1652–1653CrossRefPubMedGoogle Scholar
  13. 13.
    Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM (2006) Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57:699–704CrossRefPubMedGoogle Scholar
  14. 14.
    Cameron DR, Mortin LI, Rubio A et al (2015) Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence 6:127–131CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ioanas M, Ferrer M, Cavalcanti M et al (2004) Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med 32:938–945CrossRefPubMedGoogle Scholar
  16. 16.
    Soriano A, Marco F, Martínez JA et al (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200CrossRefPubMedGoogle Scholar
  17. 17.
    Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME (2014) Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 312:1552–1564CrossRefPubMedGoogle Scholar
  18. 18.
    Walsh TR, Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 56:657–675CrossRefPubMedGoogle Scholar
  19. 19.
    Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942CrossRefPubMedGoogle Scholar
  20. 20.
    Cui L, Iwamoto A, Lian J-Q et al (2006) Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50:428–438CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:99–139CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Baxi SM, Clemenzi-Allen A, Gahbauer A et al (2016) Vancomycin MIC does not predict 90-day mortality, readmission, or recurrence in a prospective cohort of adults with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 60:5276–5284CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Humphries RM, Pollett S, Sakoulas G (2013) A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26:759–780CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Peleg AY, Miyakis S, Ward DV et al (2012) Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS (2010) Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54:3079–3085CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Camargo IL, Neoh HM, Cui L, Hiramatsu K (2008) Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 52:4289–4299CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Humphries R, Kelesidis T, Hindler JA (2012) Importance of the frequency of susceptibility testing for the identification of daptomycin NS MRSA in blood cultures. In: Proceedings of the American Society for Microbiology 112th General Meeting, San Francisco, California, June 2012Google Scholar
  28. 28.
    Mehta S, Cuirolo AX, Plata KB et al (2012) VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:92–102CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kaatz GW, Lundstrom TS, Seo SM (2006) Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 28:280–287CrossRefPubMedGoogle Scholar
  30. 30.
    Bayer AS, Schneider T, Sahl HG (2013) Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139–158CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • J. Ruiz-Ramos
    • 1
  • P. Vidal-Cortés
    • 2
  • A. Díaz-Lamas
    • 3
  • R. Reig-Valero
    • 4
  • F. Roche-Campo
    • 5
  • M. Del Valle-Ortiz
    • 6
  • X. Nuvials-Casals
    • 7
    • 8
  • M. Ortiz-Piquer
    • 9
  • D. Andaluz-Ojeda
    • 10
  • L. Tamayo-Lomas
    • 11
  • M. A. Blasco-Navalpotro
    • 12
  • M. Rodriguez-Aguirregabiria
    • 13
  • J. Aguado
    • 14
  • P. Ramirez
    • 15
    Email author
  1. 1.Intensive Care Unit, Instituto de Investigación Sanitaria La FeHospital Universitario y Politécnico La FeValenciaSpain
  2. 2.Intensive Care UnitComplexo Hospitalario Universitario de OurenseOurenseSpain
  3. 3.Intensive Care UnitComplexo Hospitalario Universitario A CoruñaA CoruñaSpain
  4. 4.Intensive Care UnitHospital Universitario General de CastellónCastellónSpain
  5. 5.Intensive Care UnitHospital de la Santa Creu i Sant PauBarcelonaSpain
  6. 6.Intensive Care UnitHospital Universitario de BurgosBurgosSpain
  7. 7.Intensive Care UnitHospital Universitari Arnau de VilanovaLleidaSpain
  8. 8.Institut de Recerca Biomèdica (IRB Lleida)LleidaSpain
  9. 9.Intensive Care UnitHospital Lucus AugustiLugoSpain
  10. 10.Intensive Care UnitHospital Clínico Universitario ValladolidValladolidSpain
  11. 11.Intensive Care UnitHospital Universitario Río Hortega de ValladolidValladolidSpain
  12. 12.Intensive Care UnitHospital Universitario Severo OchoaLeganésSpain
  13. 13.Intensive Care UnitHospital Universitario Infanta LeonorMadridSpain
  14. 14.Infectious Disease DepartmentUniversity Hospital 12 de OctubreMadridSpain
  15. 15.Intensive Care UnitHospital Universitario y Politécnico La FeValenciaSpain

Personalised recommendations